DAPAGLIFLOZIN

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 5mg, 10mg

Dosage:

As per SMC2428: for the treatment of chronic kidney disease.
SMC Restriction:

  • in patients with an estimated glomerular filtration rate of ≥25 to ≤75 mL/min/1.73m2 at treatment initiation, AND
  • are receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless these are not tolerated or contraindicated), AND
  • have a urine albumin creatinine ratio of at least 23mg/mmol, or type 2 diabetes mellitus, or both.

Editorial Information

Document Id: F388